VJHemOnc is committed to improving our service to you

SOHO 2020 | BTK and BCL-2 inhibitor combination therapies in CLL

VJHemOnc is committed to improving our service to you

Nitin Jain

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination use of BTK inhibitors (ibrutinib and acalabrutinib) and the BCL-2 inhibitor, venetoclax, in patients with chronic lymphocytic leukemia (CLL), and clinical studies evaluating their use, including the Phase II CAPTIVATE trial (NCT02910583). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter